DocCheck AG (DE:AJ91)
XETRA:AJ91
Top Page
DocCheck AG
(XETRA:AJ91)
Select Model
Select Model
Rating:65Neutral
Price Target:
€13.00
▲(3.17% Upside)
Action:ReiteratedDate:10/28/25
DocCheck AG receives an overall stock score of 65, driven primarily by strong financial performance (score: 72, weight: 50%) with a robust balance sheet and cash flow, though limited revenue growth is a concern. Valuation is attractive (score: 85, weight: 20%) with a low P/E ratio and high dividend yield. However, bearish technical indicators (score: 45, weight: 30%) reflect short-term downward momentum, tempering the overall outlook.
Positive Factors
Profitability
Strong profitability metrics indicate efficient operations and pricing power, supporting sustained earnings and competitive positioning.
Negative Factors
Revenue Decline
A decline in revenue indicates potential market challenges or competitive pressures, which could impact future profitability and market position.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability
Strong profitability metrics indicate efficient operations and pricing power, supporting sustained earnings and competitive positioning.
Read all positive factors
DocCheck AG (AJ91) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€58.86M
Dividend Yield6.36%
Average Volume (3M)1.04K
Price to Earnings (P/E)6.1
Beta (1Y)0.65
Revenue Growth8.24%
EPS Growth140.53%
CountryDE
Employees373
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,073,816
10 Day Avg. Volume577
30 Day Avg. Volume1,041
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.06
Price to Sales (P/S)0.79
P/FCF Ratio6.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
DocCheck AG Business Overview & Revenue Model
Company Description
DocCheck AG offers marketing, customer relationship management, and e-commerce services for the healthcare sector in Europe. The company operates DocCheck portal for exchanging information on the Internet, and online and e-commerce services for he...
How the Company Makes Money
DocCheck AG generates revenue through multiple streams, primarily by providing subscription-based access to its professional network and additional services aimed at healthcare professionals. The company offers premium memberships that grant users...
DocCheck AG Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
80
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 56.55M | 53.79M | 53.41M | 60.90M | 85.92M | 63.10M |
| Gross Profit | 13.95M | 10.53M | 12.97M | 14.08M | 21.54M | 18.26M |
| EBITDA | 11.54M | 10.18M | 9.38M | 13.38M | 20.09M | 15.90M |
| Net Income | 5.87M | 5.28M | 2.27M | 6.29M | 11.40M | 9.20M |
Balance Sheet | ||||||
| Total Assets | 53.98M | 60.86M | 56.14M | 63.28M | 60.25M | 46.99M |
| Cash, Cash Equivalents and Short-Term Investments | 19.05M | 21.02M | 17.52M | 15.66M | 21.52M | 19.99M |
| Total Debt | 3.70M | 5.01M | 5.85M | 7.07M | 7.03M | 1.61M |
| Total Liabilities | 15.25M | 20.78M | 18.11M | 23.86M | 22.08M | 15.64M |
| Stockholders Equity | 38.73M | 40.08M | 37.33M | 38.57M | 37.31M | 30.91M |
Cash Flow | ||||||
| Free Cash Flow | 5.17M | 6.82M | 5.62M | -557.91K | 6.90M | 9.15M |
| Operating Cash Flow | 7.31M | 7.82M | 7.51M | 5.89M | 10.92M | 12.57M |
| Investing Cash Flow | -2.97M | -1.48M | -1.93M | -4.92M | -4.39M | -936.57K |
| Financing Cash Flow | -4.90M | -3.50M | -4.60M | -5.81M | -5.86M | -1.08M |
DocCheck AG Technical Analysis
Negative
12.60
Price Trends
12.70
Negative
12.30
Negative
12.34
Negative
Market Momentum
-0.35
Positive
27.35
Positive
21.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:AJ91, the sentiment is Negative. The current price of 12.6 is above the 20-day moving average (MA) of 12.15, below the 50-day MA of 12.70, and above the 200-day MA of 12.34, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 27.35 is Positive, neither overbought nor oversold. The STOCH value of 21.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:AJ91.
DocCheck AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | €40.40M | 14.26 | 18.76% | 3.86% | -5.72% | -25.19% | |
65 Neutral | €58.86M | 6.09 | 14.89% | 6.36% | 8.24% | 140.53% | |
60 Neutral | €1.43B | 26.77 | 4.19% | 0.20% | 1.16% | -43.53% | |
55 Neutral | €82.28M | 21.07 | -71.32% | ― | 9.48% | -481.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
DE:AJ91
DocCheck AG
11.60
2.13
22.49%
DE:COP
CompuGroup Medical
27.12
4.47
19.73%
DE:M3V
MeVis Medical Solutions
22.20
-2.86
-11.40%
DE:V3V
VITA 34
4.72
0.60
14.56%
DE:HAEK
HAEMATO AG
12.00
1.39
13.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.